In a recent survey focused on clinical development outsourcing, respondents were asked which provider type they would choose if the choice was completely up to them. The longest bar in the adjacent chart stands out—large CROs are overwhelmingly preferred by respondents for conducting Phase III trials. Large CROs are also preferred for conducting Phase IV trials (65% – an uptick of 20 ppts since 2018) Mid-size CROs are more preferred by respondents for Phase II trials (59%) Phase I provider preference is fairly mixed.

Discover more clinical development outsourcing trends in our report Clinical Development Outsourcing Models (4th Ed.)

Originally published in Life Science Leader.

View File